Seer (NASDAQ:SEER – Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Seer to post earnings of ($0.29) per share for the quarter. Seer has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.
Seer (NASDAQ:SEER – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. The business had revenue of $3.07 million during the quarter, compared to analyst estimates of $3.33 million. Seer had a negative net margin of 559.21% and a negative return on equity of 21.26%. During the same quarter in the prior year, the firm earned ($0.37) earnings per share. On average, analysts expect Seer to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Seer Price Performance
NASDAQ:SEER opened at $2.02 on Tuesday. Seer has a twelve month low of $1.46 and a twelve month high of $2.30. The company’s 50-day moving average price is $1.82 and its 200-day moving average price is $1.83.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on Seer
Seer Company Profile
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
See Also
- Five stocks we like better than Seer
- What is a Low P/E Ratio and What Does it Tell Investors?
- Intel: Is Now the Time to Be Brave?Â
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.